Healius Limited’s full-year results for FY26 demonstrate solid operational execution in a challenging environment, with underlying EBITDA growing 8.1 percent to $258.6 million despite modest revenue growth of just 2.1 percent to $1,373.2 million. The divergence between revenue and earnings growth reflects the company’s focus on margin improvement through revenue mix optimization and disciplined cost management, a strategy that has started to yield tangible results.
The pathology division, which accounts for the bulk of group revenue at $1,329.6 million, grew just 1.8 percent but drove EBITDA expansion with a 6.4 percent increase to $247.9 million. This margin recovery was achieved despite headwinds from Fair Work Commission-driven labor cost increases, which the company successfully offset through network and labour optimization that kept overall costs flat year-on-year. The mix shift toward higher-margin business lines including genomic diagnostics, clinical trials, and veterinary pathology appears to be delivering benefits, offsetting the decline in traditional GP-driven volumes which fell 0.9 percent.
The digital technology implementation phase is now complete, which management identifies as a key lever for future growth alongside artificial intelligence and automation initiatives. The company has rolled out several technology improvements including the Medway Collectors Portal, Results Portal, and a new Patient App. The Pathway laboratory information system is expected to unlock further network efficiencies gradually through FY27, positioning Healius to drive productivity improvements and potentially margin expansion in coming years.
Agilex, the smaller diagnostics business, showed stronger momentum with revenue growing 14.1 percent to $43.6 million and EBITDA surging 67.2 percent to $10.7 million. While still a modest contributor to group profitability, the acceleration suggests the company’s digital capabilities are gaining traction in this segment. The balance sheet remains sound with net debt of $32.8 million and the company operating comfortably within banking covenants.
Investors should focus on the company’s ability to sustain margin improvement as digital technology investments mature and automation gains scale. The flattening of labor costs despite external pressures is a notable achievement, though the magnitude of FWC increases remains a key risk. Execution of the Pathway network consolidation strategy and commercialization of AI initiatives will be critical to delivering sustainable earnings growth. This announcement has been flagged as price sensitive and is considered material to ASX-listed Healius Limited.
View the full ASX announcement (PDF)
About Healius Limited (ASX: HLS)
Healius Limited is Australia’s second-largest pathology provider, operating a network of pathology laboratories, diagnostic imaging centres, and day hospitals across the country. The company operates through Pathology and Imaging segments, providing medical laboratory services and diagnostic imaging services to patients and healthcare providers. Healius maintains around 2,000 collection sites and nearly 100 pathology laboratories throughout Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
